Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease

Journal of Inherited Metabolic Disease

Volumn 27, Issue 4, 2004, Pages 499-505

  Dehout, Francois ^a,c   Roland, D ^b   de Granseigne, S Treille ^a   Guillaume, B ^a   Van Maldergem, L ^b  

^a Centre Hospitalier Universitaire de Charleroi   (Belgium)

^b INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^c Hospital Civil Charleroi   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; KIDNEY DISEASE; LIPID STORAGE; MALE; MORTALITY; QUESTIONNAIRE; RARE DISEASE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; DIARRHEA; FABRY DISEASE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; ISOENZYMES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES;

EID: 4344567983     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BOLI.0000037342.59612.69     Document Type: Article

References (14)

1. Argoff CE, Barton NW, Brady RO, Ziessman HA (1998) Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 19: 887-891.
2. Eng CM, Guffon N, Wilcox WR, et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16.
3. Friedman LS, Kirkham SE, Thistlethwaite JR, Platika D, Kolodny EH, Schuffler MD (1984) Jejunal diverticulosis with perforation as a complication of Fabry's disease. Gastroenterology 86: 558-563.
4. Gold KF, Pastores GM, Botteman MF, et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11: 317-327.
5. Jardine DL, Fitzpatrick MA, Troughton WD, Tie AB (1994) Small bowel ischaemia in Fabry's disease. J Gastroenterol Hepatol 9: 201-204.
6. MacDermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775.
7. MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750-760.
8. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281: 249-254.
9. Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD (2002) Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 11: 127-133.
10. Pastores GH and Thadhani R (2002) Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther 2(3): 325-333.
11. Pintos Morell G (2002) [Fabry's disease: diagnosis in the pediatric age group]. An Esp Pediatr 57: 45-50.
12. Rowe JW, Gilliam JI, Warthin TA (1974) Intestinal manifestations of Fabry's disease. Ann Intern Med 81: 628-631.
13. Schiffmann R, Kopp JB, Austin HA 3rd, et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749.
14. Sheth KJ, Werlin SL, Freeman ME, Hodach AE (1981) Gastrointestinal structure and function in Fabry's disease. Am J Gastroenterol 76: 246-251.